INVITRIS
LIVE

Serial Number

99438872

Owner

Invitris GmbH

Attorney

Keith A. Weltsch

Filing Date

Oct 12, 2025

Add to watchlist:

No watchlists yet
View on USPTO

INVITRIS Trademark

Serial Number: 99438872

INVITRIS is a trademark filed by Invitris GmbH on October 12, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Invitris GmbH (2 trademarks)

Forstenrieder Allee 84 B
Munich 81476 , DE

Entity Type: 99

Trademark Details

Filing Date

October 12, 2025

Registration Date

Not Registered

Goods & Services

Anti-microbial preparations for controlling biofilms and inhibition of bacteria; Anti- bacterial preparations, namely, sprays, creams or devices for intravenous applications; Anti-bacterial pharmaceuticals; Medicine for the prevention and treatment of infectious diseases, Human or animal additives in the nature of dietary supplements for medical purposes; Food supplements for veterinary use; bacteriophages being pharmaceutical, medical, and veterinary preparations for prevention and treatment of bacteria-based diseases and disorders; Antibiotics; Anti-infectives; Preparations for microbiome health

manufacturing of proteins, nucleic acids, metabolites, and other biomolecules for others using cell-free biosynthesis systems; contract manufacturing in the field of cell-free biosynthesis; manufacturing consulting services in the field of cell-free biosynthesis

Biomedical research services in the field of cell-free biosynthesis; research and development for the pharmaceutical industry in the field of cell-free biosynthesis; pharmaceutical research and development in the field of cell-free biosynthesis; biotechnology research in the field of cell-free biosynthesis; consultancy relating to pharmaceutical research and development in the field of cell-free biosynthesis; consultancy relating to research and development in the field of therapeutics; biological research, clinical research, and medical research in the field of cell-free biosynthesis; research and development in the pharmaceutical and biotechnology fields in the field of cell-free biosynthesis; clinical research in the field of cell-free biosynthesis; medical research in the field of cell-free biosynthesis; veterinary research in the field of cell-free biosynthesis; scientific research and development in the field of cell-free biosynthesis; bacteriological research in the field of cell-free biosynthesis; provision of research services in the field of cell-free biosynthesis; research and development services relating to bacteriophages in the field of cellfree biosynthesis; research and development in the field of microbiomes in the field of cell-free biosynthesis; research and development services relating to anti-infectives in the field of cell-free biosynthesis

Filing History

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 4, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 4, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 4, 2026 GNRN
NON-FINAL ACTION E-MAILED
Mar 4, 2026 GNRT
NON-FINAL ACTION WRITTEN
Mar 4, 2026 CNRT
ASSIGNED TO EXAMINER
Mar 2, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 11, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Oct 12, 2025 MAFR
NEW APPLICATION ENTERED
Oct 12, 2025 NWAP